申请人:Ranbaxy Laboratories Limited
公开号:US07781460B2
公开(公告)日:2010-08-24
The present invention relates to isoxazoline derivatives of structure Ia, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. Compounds disclosed herein can be useful in the treatment of CNS disorders, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases especially in humans. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and their use as phosphodiesterase (PDE) type IV inhibitors.
本发明涉及结构式Ia的异氧嗪衍
生物,可用作
磷酸二酯酶(PDE)IV型的选择性
抑制剂。本文所披露的化合物可用于治疗中枢神经系统疾病、艾滋病、哮喘、关节炎、支气管炎、慢性阻塞性肺疾病(
COPD)、
银屑病、过敏性鼻炎、休克、特应性皮炎、克罗恩病、成人呼吸窘迫综合征(ARDS)、嗜酸性肉芽肿、过敏性结膜炎、骨关节炎、溃疡性结肠炎和其他炎症性疾病,特别是在人类中。本文提供了制备所披露化合物的方法,以及含有所披露化合物的制药组合物,以及它们作为
磷酸二酯酶(PDE)IV型
抑制剂的用途。